SABS — SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 63
- Website: https://www.sab.bio
Latest SEC filings for SABS
- 424B3 — 2026-08-21
- 10-Q — 2026-08-06
- 8-K — 2026-07-07
- 8-K — 2026-06-18
- 10-Q — 2026-05-12
- 8-K — 2026-05-04
- 8-K — 2026-03-19
- 424B5 — 2026-03-19
- 424B5 — 2026-03-17
- 8-K — 2026-03-10
Latest SABS news
- — SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
- — SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated “Moderate Buy” by Sell-Side Analysts
Educational tool only — not investment advice.